The Future of JAK Inhibitors

Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option?

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. This innovative drug class has faced dizzying twists, turns and falls within the landscape of safety acceptability. Yet despite the hurdles JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted.

Driven by the sheer scale of the Immune-Mediated Inflammatory Diseases (IMIDs) treatment market and clear scenario of unmet patient need, the JAKs pipeline currently comprises no fewer than 45 therapeutic candidates. 1 In different stages of development, they are in a whole slew of IMID fields – and their journey is far from over.

JAK inhibitors are an oral class of therapeutics exciting to biopharma companies, investors, patients and physicians alike. Clinical results promise patients in multiple indications effective and more convenient treatment options. The first assets to enter the market, with approval for Rheumatoid Arthritis (RA), were tofacitinib (now also approved for Psoriatic Arthritis and Ulcerative Colitis) and baricitinib, followed by upadacitinib (RA).

First-generation JAKs have proven spectacularly efficacious both in clinical trials and in the clinic in treating inflammatory and autoimmune diseases – however, nearly all are facing an imbalance between safety and efficacy.

The result? JAKs’ rise in market success – for now – has hit unexpected turbulence.

Deallus JAK Inhibitors White Paper
DOWNLOAD WHITEPAPER

You may also be interested in…

  • Medical Insights to Maximise Product Value

Maximise product value through Medical Insights

Medical Insights is emerging as a transformative organisational capability within Medical Affairs that aims to capture real-world insights through medical channels and use them to maximise product and portfolio value.

Deallus sponsoring and speaking at the Pharma CI EU Conference

We are excited to be sponsoring and speaking at the Pharma CI EU conference, held in Rome on 30-31 March 2023. Julie Munch Khan, COO, and Stephen Small, Senior Principal at Deallus will be joining other Competitive Intelligence experts across Pharma, Biotech and Medical Devices.

  • Policies for rare diseases in China Feb 2023

Overview of current policy for rare disease in China

For the first time after decades of negligence in this area, China published the First List of Rare Diseases (FLRDs). This was a key step in improving and standardising the regulatory system of rare disease management, orphan drug development, and review and approval.

  • HIV & AIDS Medication

HIV/AIDS

Human immunodeficiency virus (HIV) is the virus that is responsible for Acquired Immune Deficiency Syndrome (AIDS). HIV continues to be a major global public health issue having claimed the lives of 36.3 million people so far, according to World Health Organization (WHO).